NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $2.88 0.00 (0.00%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$2.92 +0.04 (+1.25%) As of 09/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Perspective Therapeutics Stock (NYSEAMERICAN:CATX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CATX alerts:Sign Up Key Stats Today's Range$2.77▼$2.9450-Day Range$2.70▼$3.4852-Week Range$1.96▼$6.16Volume11.63 million shsAverage Volume1.11 million shsMarket Capitalization$328.75 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingBuy Company Overview Perspective Therapeutics, Inc. is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue. Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals. Its pipeline has included VMT01, a targeted alpha therapy being studied for patients with metastatic melanoma, and VMT-α-NET, a program designed to target somatostatin receptor-positive neuroendocrine tumors. These programs are being evaluated in clinical studies to assess their safety, targeting capabilities and potential therapeutic benefits. The company is headquartered in Seattle, Washington, and is developing the infrastructure and manufacturing capabilities needed to support radiopharmaceutical production and clinical development. Perspective Therapeutics serves the oncology market through its research and development activities, with a focus on cancers that can be identified through molecular targets and treated using targeted alpha-particle therapy.AI Generated. May Contain Errors. Read More Perspective Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCATX MarketRank™: Perspective Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialPerspective Therapeutics has a consensus price target of $11.50, representing about 299.3% upside from its current price of $2.88.Amount of Analyst CoveragePerspective Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Perspective Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.98) to ($1.08) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Perspective Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.09% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 23.64, which indicates bearish sentiment.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.09 News SentimentPerspective Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Perspective Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows6 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.99% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CATX Stock News HeadlinesWedbush Reiterates Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)September 17 at 1:48 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)September 16 at 12:10 PM | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 19 at 1:00 AM | Weiss Ratings (Ad)Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α ...September 14, 2026 | markets.businessinsider.comPerspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid TumorsSeptember 14, 2026 | quiverquant.comQPerspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid TumorsSeptember 14, 2026 | globenewswire.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Rating of "Buy" by AnalystsSeptember 12, 2026 | americanbankingnews.comPerspective Therapeutics Announces Acceptance of Updated [212Pb]VMT-α-NET Data for Presentation at 2026 ENA SymposiumSeptember 11, 2026 | quiverquant.comQSee More Headlines CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $2.75 on January 1st, 2026. Since then, CATX shares have increased by 4.7% and is now trading at $2.88. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. The company earned $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative trailing twelve-month return on equity of 41.92%. When did Perspective Therapeutics' stock split? Perspective Therapeutics's stock reverse split on Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' top institutional shareholders include Seven Fleet Capital Management LP (0.29%), Bank of New York Mellon Corp (0.26%), Portland Investment Counsel Inc. (0.22%) and Wellington Management Group LLP (0.06%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Jonathan Robert Hunt, Johan M Spoor, Juan Graham, Heidi Henson and Robert F Williamson III. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/10/2026Today9/19/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, CATX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:CATX Previous SymbolNYSE:CATX CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees166Year FoundedN/APrice Target and Rating Average Price Target for Perspective Therapeutics$11.50 High Price Target$14.00 Low Price Target$5.00 Potential Upside/Downside+299.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.12 million Net Margins-28,467.97% Pretax Margin-28,710.03% Return on Equity-41.92% Return on Assets-34.42% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual Sales$880 thousand Price / Sales373.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book1.03Miscellaneous Outstanding Shares114,150,000Free Float110,739,000Market Cap$328.75 million OptionableOptionable Beta1.80 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSEAMERICAN:CATX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
